Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Galantamine for Alzheimer's disease.

J Olin1, L Schneider

  • 1Adult and Geriatric Treatment and Preventative Interventions Branch, National Institute of Mental Health, NIMH, Room 7160, MSC 9635, 6001 Executive Blvd., Bethesda, Maryland 20892-9635, USA. jolin@mail.nih.gov

The Cochrane Database of Systematic Reviews
|May 2, 2001
PubMed
Summary

Galantamine demonstrates significant treatment effects for Alzheimer's disease at daily doses of 16-32 mg/d over 3-6 months. Higher doses showed improvements in global ratings and cognitive function, though with increased discontinuation rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Performance and nutrient composition of black soldier fly larvae fed diets with various protein concentrations throughout the life cycle.

Animal : an international journal of animal bioscience·2025
Same author

Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015-22: experience from an HIV clinic in Paris, France.

The Journal of antimicrobial chemotherapy·2025
Same author

Canadian Surgery Forum: Abstracts of presentations to the Annual Meetings of the Canadian Association of Bariatric Physicians and Surgeons, Canadian Association of General Surgeons, Canadian Association of Thoracic Surgeons, Canadian Hepato-Pancreato-Biliary Association, Canadian Society of Surgical Oncology, Canadian Society of Colon and Rectal Surgeons, Vancouver, BC, Sept. 17-21, 2013.

Canadian journal of surgery. Journal canadien de chirurgie·2025
Same author

No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens.

The Journal of antimicrobial chemotherapy·2025
Same author

Knowledge, attitudes and practices on prevention and control of high-consequence infectious diseases and critical care among intensive care personnel in Rwanda: a cross-sectional survey.

Infection prevention in practice·2024
Same author

Extrahepatic Bile Duct Organoids as a Model to Study Ischemia/Reperfusion Injury During Liver Transplantation.

Transplant international : official journal of the European Society for Organ Transplantation·2024

Area of Science:

  • Pharmacology and Neurology
  • Clinical Trials and Therapeutics

Background:

  • Galantamine, an acetylcholinesterase inhibitor and nicotinic receptor modulator, is synthesized and used for Alzheimer's disease.
  • Previous studies suggested mild cognitive benefits; recent multicentre trials show positive findings, leading to regulatory approvals in some regions.

Purpose of the Study:

  • To assess the clinical effects of galantamine in patients with probable Alzheimer's disease.
  • To investigate potential moderators of galantamine's treatment effect.

Main Methods:

  • Systematic review of randomized, double-blind, parallel-group trials comparing galantamine with placebo for over 4 weeks.
  • Searched multiple databases (Cochrane, EMBASE, MEDLINE, etc.) and clinical trial registers.
  • Extracted and pooled data on cognitive (ADAS-cog), global (CIBIC-plus), and functional (ADCS-ADL, DAD) outcomes; analyzed trial duration and dose as moderators.

Related Experiment Videos

Main Results:

  • Galantamine showed significant treatment effects at daily doses of 16-32 mg/d over 3-6 months.
  • Significant improvements in global ratings and cognitive function (ADAS-Cog) were observed at doses of 24-32 mg/d for 6 months.
  • Higher doses (24-32 mg/d) were associated with increased trial discontinuation rates, unlike lower doses or placebo.

Conclusions:

  • Galantamine at 16-32 mg/d is effective for probable Alzheimer's disease over 3-6 months.
  • Dose and trial duration are key factors influencing treatment efficacy and tolerability.
  • Further research is needed to optimize dosing and minimize adverse effects like gastrointestinal issues and discontinuation.